Medtimo, a wholly owned subsidiary of Biorad Medisys Private Limited, has filed a patent infringement complaint in the US District Court of the District of Delaware against Allurion Technologies. Medtimo’s complaint claims Allurion's gastric balloon system infringes upon Medtimo's intellectual property. This definitive action follows Allurion’s recent unsuccessful challenge of Medtimo’s patent rights in the US Patent and Trademark Office (USPTO). The complaint alleges that Al

The first peer-reviewed study on the consecutive use of the Allurion’s Smart Capsule, a first of its kind, swallowable, procedure-less weight-loss device, has revealed the multi-centre, retrospective outcomes demonstrated that two consecutive treatments can achieve average total body weight loss of 22.1% (19.3 kg), results comparable to bariatric surgery and high-dose GLP-1 therapy. The Allurion Smart Capsule is designed to be swallowed during a brief outpatient visit, filled

Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need. Akero’s fibroblast growth factor 21 (FGF21) analogue efruxifermin (EFX) is a potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH). EFX is currently in phase 3 development for the treatment of patient

There have been reports that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may also have the potential to treat alcohol and drug...

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, according to research presented at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25). GLP-1 receptor agonists are now widely prescribed for individuals with type 2 diabetes and weight loss, with a 700% increase in usage reported in the US between 2019 and 2023. These medications alter glucose metabolism, gastric motility and sympathetic to

High cost or insurance-related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for...

High metabolic activity of visceral fat may be associated with more aggressive endometrial cancer, according to a presentation, ‘Visceral...

There has been a 16-fold increase in the use of weight loss drugs among patients before metabolic and bariatric surgery, signalling an...

In patients with steatotic liver disease (SLD), metabolic bariatric surgery (MBS) is associated with significant reductions in the rates...

Roux-en-Y Gastric bypass (RYGB) is an effective approach for the management of obesity in selected adolescent patients, resulting in...

Endevica Bio has announced that the co-agonism of the melanocortin-3 and melanocortin-4 receptors (MC3/4R) drives robust weight loss,...

An international study led by Queensland University of Technology (QUT) researchers has found that bariatric surgery improves work...